Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

Abstract Background Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2− MBC); however, resistance is common and poorly understo...

Full description

Bibliographic Details
Main Authors:	Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee, Jisook Lee, Miso Kim, Hyun Seon Kim, Scott L. Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen Dann, Yu-Jin Kim, Diane R. Fernandez, Jiwon Koh, Shuoguo Wang, Song Yi Park, Shibing Deng, Eric Powell, Rupesh Kanchi Ravi, Jadwiga Bienkowska, Paul A. Rejto, Woong-Yang Park, Zhengyan Kan
Format:	Article
Language:	English
Published:	BMC 2023-07-01
Series:	Genome Medicine
Subjects:	Advanced breast cancer Drug resistance Genomic profile Gene expression profiling Palbociclib Homologous recombination repair deficiengy (HRD)
Online Access:	https://doi.org/10.1186/s13073-023-01201-7

Similar Items

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
by: Soohyeon Lee, et al.
Published: (2022-04-01)

The discrepancy of somatic BRCA1/2 pathogenic variants from two different platforms in epithelial ovarian, fallopian tube, and peritoneal cancer
by: Ji Hyun Kim, et al.
Published: (2024-10-01)

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
by: Chang Gon Kim, et al.
Published: (2023-01-01)

Palbociclib in the treatment of recurrent ovarian cancer
by: Dai Wee Lee, et al.
Published: (2020-11-01)

Oral ulcers in patients treated with palbociclib: a case report
by: Alande Cédric, et al.
Published: (2018-06-01)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
by: Alexandre Le Marouille, et al.
Published: (2021-10-01)

Determination of palbociclib by high performance liquid chromatography
by: Xiaodong SHI, et al.
Published: (2017-08-01)

Population Pharmacokinetics of Palbociclib in a Real-World Situation
by: Bernard Royer, et al.
Published: (2021-02-01)

Palbociclib as an Antitumor Drug: A License to Kill
by: Agnieszka Łupicka-Słowik, et al.
Published: (2024-11-01)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
by: Chenxin Duan, et al.
Published: (2021-12-01)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
by: Yi-Bo Hou, et al.
Published: (2019-08-01)

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice
by: L. G. Zhukova, et al.
Published: (2019-06-01)

Palbociclib in metastatic breast cancer: current evidence and real-life data
by: Francesco Serra, et al.
Published: (2019-07-01)

Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice
by: Filipa Alves da Costa, et al.
Published: (2023-06-01)

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer
by: Perrine Courlet, et al.
Published: (2022-06-01)

Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells
by: Lindsey R. Conroy, et al.
Published: (2020-07-01)

expHRD: an individualized, transcriptome-based prediction model for homologous recombination deficiency assessment in cancer
by: Jae Jun Lee, et al.
Published: (2024-07-01)

Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma
by: Daniela Maria Calucică, et al.
Published: (2022-12-01)

Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
by: François Poumeaud, et al.
Published: (2022-12-01)

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
by: Vittorio Gebbia
Published: (2023-04-01)

Human Resource Development Climate in Banks
by: Dr.Sasmita Nayak
Published: (2016-06-01)

Load Profile Extraction by Mean-Shift Clustering with Sample Pearson Correlation Coefficient Distance
by: Nakyoung Kim, et al.
Published: (2018-09-01)

Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
by: Karen Gelmon, et al.
Published: (2021-10-01)

Improve BBB Penetration and Cytotoxicity of Palbociclib in U87-MG Glioblastoma Cells Delivered by Dual Peptide Functionalized Nanoparticles
by: Yu-Chen Lo, et al.
Published: (2023-10-01)

Corrigendum: Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
by: François Poumeaud, et al.
Published: (2023-02-01)

Palbociclib induces DNA damage and inhibits DNA repair to induce cellular senescence and apoptosis in oral squamous cell carcinoma
by: Tong-Hong Wang, et al.
Published: (2021-09-01)

Key Schedule against Template Attack-Based Simple Power Analysis on a Single Target
by: Yoo-Seung Won, et al.
Published: (2020-05-01)

Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report
by: Vardan Nersesjan, et al.
Published: (2019-10-01)

PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
by: Ernest H Law, et al.
Published: (2023-04-01)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
by: Hope S. Rugo, et al.
Published: (2023-06-01)

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
by: Cha Len Lee, et al.
Published: (2023-12-01)

Single-cell phenotypes revealed as a key biomarker in bacterial–fungal interactions: a case study of Staphylococcus and Malassezia
by: Eun Sun Lyou, et al.
Published: (2023-12-01)

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3
by: Hope S. Rugo, et al.
Published: (2022-12-01)

Gene expression profiling of chondrogenic differentiation by dexamethasone-conjugated polyethyleneimine with SOX trio genes in stem cells
by: Se Won Yi, et al.
Published: (2018-12-01)

Gender-specific alteration of steroid metabolism and its impact on viral replication in a mouse model of hepatitis B virus infection
by: Eun-Sook Park, et al.
Published: (2024-12-01)

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
by: Engel-Nitz NM, et al.
Published: (2023-04-01)

Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
by: Tina Jost, et al.
Published: (2021-10-01)

Study on the Estimation Method of Wind Resistance Considering Self-Induced Wind by Ship Advance Speed
by: Hyounggil Park, et al.
Published: (2024-09-01)

Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
by: David S. Shulman, et al.
Published: (2023-07-01)